journal
https://read.qxmd.com/read/38644547/car-t-cell-therapy-unravelling-its-potential-in-extra-nodal-diffuse-large-b-cell-lymphoma
#1
JOURNAL ARTICLE
Salman J Khan, Muhamad Alhaj Moustafa
No abstract text is available yet for this article.
April 18, 2024: Chinese Clinical Oncology
https://read.qxmd.com/read/38644544/adjuvant-radiotherapy-versus-observation-after-gross-total-resection-of-who-grade-ii-ependymoma-a-systematic-review-and-individual-participant-data-meta-analysis
#2
JOURNAL ARTICLE
Yilong Zheng, Shi Hui Ong, Vincent Diong Weng Nga, Balamurugan Vellayappan
BACKGROUND: The role of adjuvant radiotherapy (RT) after gross total resection (GTR) of the World Health Organization (WHO) grade II ependymoma is controversial. Therefore, we aimed to compare the outcomes of adjuvant RT against observation after GTR of WHO grade II ependymoma. We also compared the outcomes of adjuvant RT against observation after subtotal resection (STR) of WHO grade II ependymoma and performed further subgroup analysis by age and tumor location. METHODS: PubMed and Embase were systematically reviewed for studies published up till 25 November 2022...
April 17, 2024: Chinese Clinical Oncology
https://read.qxmd.com/read/38644546/narrative-review-of-the-utility-of-magnetic-resonance-imaging-in-radiotherapy-for-cervical-cancer
#3
JOURNAL ARTICLE
Jiwoo Lee, Carminia Lapuz, Richard Khor, Eddie Lau, Natalie Yang, Adeline Lim, Farshad Foroudi, Sweet Ping Ng
BACKGROUND AND OBJECTIVE: In radiotherapy (RT) for locally advanced cervical cancer, high soft tissue contrast on magnetic resonance imaging (MRI) can ensure accurate delineation of target volumes (TVs) and optimal dose distribution to the RT target and organs at risk (OAR). MRI-guided adaptive RT (MRIgART) is a novel technology that revises RT plans according to anatomical changes occurring throughout the treatment to improve target coverage and minimise OAR toxicity. This review aims to assess the evidence and gaps of MRI use in RT planning and MRIgART in the treatment of cervical cancer, as well as challenges in its clinical implementation...
April 13, 2024: Chinese Clinical Oncology
https://read.qxmd.com/read/38644545/stepwise-analysis-of-thyroid-diagnostic-modalities-with-genomic-imprinting-detection
#4
JOURNAL ARTICLE
Wanting Yang, Ming Yin, Jiehong Zhou, Yun Zhu, Beibei Ye, Hui Shi, Bingjie Zhang, Can Yue, Yifeng Zhang, Hongxun Wu, Haohao Li, Xuliang Xia, Shufang Yang, Buyun Ma
BACKGROUND: The current preoperative malignancy risk evaluation for thyroid nodules involves stepwise diagnostic modalities including ultrasonography, thyroid function serology and fine-needle aspiration (FNA) cytopathology, respectively. We aimed to substantiate the stepwise contributions of each diagnostic step and additionally investigate the diagnostic significance of quantitative chromogenic imprinted gene in-situ hybridization (QCIGISH)-an adjunctive molecular test based on epigenetic imprinting alterations...
April 12, 2024: Chinese Clinical Oncology
https://read.qxmd.com/read/38600808/clinical-status-and-perspective-on-the-application-of-immunotherapy-combined-with-chemotherapy-in-advanced-non-small-cell-lung-cancer-a-review
#5
JOURNAL ARTICLE
Tianming Wang, Liang Zhang, Ying Cheng
The therapeutic landscape of advanced non-small cell lung cancer (NSCLC) has been significantly improved by developing immunotherapy represented by programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immune checkpoint inhibitors (ICI). Furthermore, immunotherapy combined with chemotherapy is an essential treatment strategy for driver-negative advanced NSCLC, especially in a population with PD-L1 <50%, and leads to long-term survival in the entire population regardless of the PD-L1 expression status...
April 8, 2024: Chinese Clinical Oncology
https://read.qxmd.com/read/38600807/anaerobic-gram-negative-rod-bacteremia-as-a-marker-of-gastrointestinal-cancer-in-japanese-patients-a-single-center-retrospective-study
#6
JOURNAL ARTICLE
Eiko Abe, Kazuhiro Ishikawa, Kazunari Onishi, Nobuyoshi Mori
BACKGROUND: Gram-negative rod (GNR) bacteremia has been suggested as a clinical marker of occult cancer; however, no studies are available in this regard in the Japanese population. Here, we investigated the risk factors for gastrointestinal cancer with GNR bacteremia. METHODS: Patients with GNR bacteremia admitted to St. Luke's International Hospital between January 2011 and July 2021 were included. The clinical data of patients with and without cancer, 1 year before and after GNR bacteremia diagnosis, were compared...
April 8, 2024: Chinese Clinical Oncology
https://read.qxmd.com/read/38600809/ad-aura-a-fresh-breeze-for-patients-with-resected-egfr-mutant-non-small-cell-lung-cancer
#7
JOURNAL ARTICLE
Nicole Conci, Andrea De Giglio, Francesca Sperandi, Barbara Melotti, Francesco Gelsomino
No abstract text is available yet for this article.
April 3, 2024: Chinese Clinical Oncology
https://read.qxmd.com/read/38462921/the-impressive-efficacy-of-anti-g-protein-coupled-receptor-class-c-group-5-member-d-chimeric-antigen-receptor-t-cells-in-patients-with-relapsed-or-refractory-multiple-myeloma
#8
JOURNAL ARTICLE
https://read.qxmd.com/read/38378474/european-society-of-medical-oncology-esmo-guidelines-for-oncogene-addicted-metastatic-non-small-cell-lung-cancer-nsclc-a-personalized-treatment-for-each-patient
#9
JOURNAL ARTICLE
Guillermo Suay, Francisco Aparisi, Oscar Juan-Vidal
No abstract text is available yet for this article.
February 20, 2024: Chinese Clinical Oncology
https://read.qxmd.com/read/38378473/the-effects-of-radiation-therapy-on-the-heart-implications-for-management
#10
JOURNAL ARTICLE
Kristin Hsieh, Alexandra E Hotca, Juliana Runnels, Daniel Cherry, Julie R Bloom, Catherine Yu, Anthony D Nehlsen, Lucas Resende Salgado, Kunal K Sindhu
Chemotherapy, radiotherapy, and surgery constitute the three primary modalities employed in the treatment of patients with cancer. Radiotherapy, in particular, is a mainstay of treatment for patients with cancers of the breast, esophagus, lung, and lymph nodes. Prior studies have shown, however, that radiotherapy can impact the heart. Radiation exposure, in fact, can lead to pathophysiological changes that may result in short- and long-term radiation-induced cardiac toxicities. Such toxicities can cause substantial morbidity and may manifest clinically in the weeks to years after the completion of treatment...
February 20, 2024: Chinese Clinical Oncology
https://read.qxmd.com/read/38711180/intralesional-curettage-and-surgical-adjuvants-in-the-treatment-of-giant-cell-tumor-of-bone-meta-analysis-and-systematic-review
#11
JOURNAL ARTICLE
Ao Leng, Haojie Gao, Jiacheng Li, Lingzhi Meng, Qi Wang, Liangbi Xiang
BACKGROUND: The ideal treatment for giant cell tumor of bone (GCTB) is still controversial. Various surgical adjuvants have been introduced following intralesional curettage to improve local control rates. However, findings from relevant studies are inconsistent, and no consensus has been reached. The purpose of this study is to determine what intraoperative adjuvant is effective in decreasing the recurrence of GCTB. METHODS: We performed a systematic review and meta-analysis of articles published in the PubMed and Embase electronic databases which assessed the recurrence rate of GCTB following intralesional curettage with or without various surgical adjuvants...
April 2024: Chinese Clinical Oncology
https://read.qxmd.com/read/38711179/new-surgical-strategies-from-endoscopical-resection-to-liver-transplantation-for-hepatobiliopancreatic-tumours
#12
EDITORIAL
Giovanni Battista Levi Sandri
No abstract text is available yet for this article.
April 2024: Chinese Clinical Oncology
https://read.qxmd.com/read/38711178/treatment-strategies-for-borderline-resectable-pancreatic-neuroendocrine-tumors-a-narrative-review
#13
REVIEW
Jin Y Chang, Samantha M Ruff, Jordan M Cloyd
BACKGROUND AND OBJECTIVE: Well-differentiated pancreatic neuroendocrine tumors (pNETs) are a group of rare, heterogeneous tumors that originate in the endocrine tissue of the pancreas and account for 1-2% of all pancreatic neoplasms. The majority of pNETs are non-functional and typically follow a more indolent course. Especially at early stages, the primary management of pNETs is surgical resection which is associated with relatively low rates of recurrence and excellent long-term prognosis...
April 2024: Chinese Clinical Oncology
https://read.qxmd.com/read/38711177/advancements-and-future-directions-in-positron-emission-tomography-guided-radiotherapy-a-narrative-review
#14
REVIEW
Shahil Mehta, Christine Yang, Hossein Jadvar, Patrick M Colletti, Peter S Conti, Lijun Ma, Eric L Chang, Jason C Ye
BACKGROUND AND OBJECTIVE: Positron emission tomography (PET) imaging has been useful in delineating tumor volumes and allowing for improved radiation treatment. The field of PET-guided radiotherapy is rapidly growing and will have significant impact on radiotherapy delivery in the future. This narrative review provides an overview of the current state of PET-guided radiotherapy as well as the future directions of the field. METHODS: For this narrative review, PubMed was searched for articles from 2010-2023...
April 2024: Chinese Clinical Oncology
https://read.qxmd.com/read/38372057/clinical-features-and-mutation-analysis-of-class-1-2-3-braf-mutation-colorectal-cancer
#15
JOURNAL ARTICLE
Yingying Huang, Wenzhuo Jia, Gang Zhao, Yunbo Zhao, Shuai Zhang, Zhongkang Li, Guoju Wu
BACKGROUND: BRAF (B-Raf proto-oncogene, serine/threonine kinase)-mutated colorectal cancer (CRC) still has poor prognostic. The efficacy of BRAF inhibitor is unpredictable just that intrinsic genetic complexity, immune microenvironment and partially unknown reason. Understanding the co-mutation mechanism can help improve treatment and follow-up strategies. METHODS: We retrospectively analyzed 35 (BRAF-mutated/BRAF wild-type) Chinese CRC and 125 Western CRC who underwent next-generation sequencing (NGS)...
February 5, 2024: Chinese Clinical Oncology
https://read.qxmd.com/read/38372061/radiation-free-conditioning-in-acute-lymphoblastic-leukemia-is-it-time
#16
JOURNAL ARTICLE
Manuel Espinoza-Gutarra, Razan Mohty, Omer Jamy
No abstract text is available yet for this article.
February 4, 2024: Chinese Clinical Oncology
https://read.qxmd.com/read/38372059/prehabilitation-programs-in-liver-resection-a-narrative-review
#17
JOURNAL ARTICLE
En Qi Toh, Hoi Pong Nicholas Wong, Jia Dong James Wang, Matthias Yi Quan Liau, Yi Fang Tan, Vishalkumar Girishchandra Shelat
BACKGROUND AND OBJECTIVE: Liver resection (LR) is a commonly performed surgical procedure for the management of hepatocellular carcinoma and other liver conditions. Despite its benefits in providing patients a potential cure, it is also associated with significant postoperative complications and prolonged recovery periods. In recent years, pre-operative rehabilitation (prehabilitation) has emerged as an up-and-coming strategy to optimize patients' physical, psychological and functional status before LR, leading to improved surgical and patient postoperative outcomes...
February 2, 2024: Chinese Clinical Oncology
https://read.qxmd.com/read/38453659/personalized-radiation-therapy-for-glioblastoma
#18
JOURNAL ARTICLE
Waqar Haque, E Brian Butler, Bin S Teh
Glioblastoma is the most common primary brain tumor with an estimated 14,000 Americans diagnosed with this disease annually. This disease is treated with maximal surgical resection followed by adjuvant radiation therapy. Radiation therapy was initially delivered to the whole brain and with no concurrent or adjuvant systemic therapy. Advances in imaging and treatment delivery have allowed for partial brain irradiation to minimize radiation dose to normal structures, as well as sparing structures important for memory such as the hippocampus, decreasing morbidity and toxicity...
February 2024: Chinese Clinical Oncology
https://read.qxmd.com/read/38453658/perioperative-or-neoadjuvant-chemotherapy-for-locally-advanced-gastric-or-gastroesophageal-junction-cancer-from-independent-evidence-in-the-west-the-east-and-japan-to-global-collaboration
#19
REVIEW
Izuma Nakayama, Manabu Ohashi, Souya Nunobe
The survival outcome of patients with locally advanced gastric or gastroesophageal junction (G/GEJ) cancer remains unsatisfactory, and improvements in survival and recurrence remain urgent issues for clinicians worldwide. Prior to the 2000s, locally advanced G/GEJ was a different disease between the West and the East regarding diagnosis, surgery, and prognosis. However, recent advances in medical oncology have set the stage for harmonization. Herein, this review highlights clinical trials of perioperative or neoadjuvant chemotherapy conducted during the past two decades to provide insights into future directions...
February 2024: Chinese Clinical Oncology
https://read.qxmd.com/read/38453657/how-to-use-anti-pd-1-therapy-in-gastric-cancer-the-approach-in-the-united-states
#20
JOURNAL ARTICLE
David H Ilson
Gastric cancer is a leading global cause of cancer-related mortality. In the past, survival achieved in metastatic disease with chemotherapy was less than 1 year. The advent of immune checkpoint inhibitors has changed the treatment of gastric cancer. With demonstration of single agent activity for anti-programmed cell death protein 1 (anti-PD-1) agents in gastric cancer with a particularly high degree of activity in microsatellite instability (MSI) high cancers, global clinical trials added nivolumab and pembrolizumab to first line chemotherapy...
February 2024: Chinese Clinical Oncology
journal
journal
47887
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.